A carregar...
Publicação
Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 259.86 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.
Descrição
Funding: Tecnologia (FCT), Portugal (SFRH/BPD/109347/ 2015; PTDC/NEU-OSD/5644/2014). TFO is supported by the DFG Center for Nanoscale Microscopy of the Brain (CNMPB) and by an EU Joint Programme – Neurodegenerative Disease Research (JPND) project (aSynProtec). The project is supported through the following funding organisations under the aegis of JPND – www.jpnd.edu (BMBF).
Palavras-chave
Glycation Maillard-reaction Parkinson’s disease alpha-synuclein SDG 3 - Good Health and Well-being